Par launches authorized generic Carafate
Endo's Par unit is introducing an authorized generic of Allergan's Carafate (sucralfate) oral suspension 1gm/10 mL.
"Par is proud to partner with Allergan to bring the authorized generic of Carafate to patients," said Domenic Ciarico, Endo’s executive vice president and chief commercial officer, sterile and generics. “We are pleased to add this product to our portfolio and continue Par's tradition of being a reliable, quality supplier."
Sucralfate oral suspension had a market value of approximately $285 million for the 12 months ended Nov. 30, 2019, according to IQVIA.